HSV-1 vs HSV-2: Differences, Symptoms, and How to Test

Published: December 2024 | Last updated: May 2026

Most people who carry HSV-1 or HSV-2 have never been told they do. The two viruses share a name and most of their basic biology, yet they spread differently, recur differently, and feel different for the people living with them. This guide covers what each one does, how transmission actually works, what at-home and clinic testing can and cannot tell you, and which common beliefs about herpes are simply wrong.

A note on the publisher: stdrapidtestkits.com sells at-home STI testing kits, and we recommend a product only when it fits the reader's concern. The herpes kits we sell are fingerstick blood antibody tests, useful at the right time after exposure and explained plainly below. For an active sore or lesion, the right tool is a clinician-administered swab PCR, which we do not sell; we flag that distinction wherever it matters.

How HSV-1 and HSV-2 differ

HSV-1 and HSV-2 are members of the human herpesvirus family. Their genomes are roughly 50 percent similar, and they share most of the same machinery for entering cells, replicating, and establishing lifelong latency in nerve tissue. What separates them is which nerve cluster each virus settles into once it gets there.

HSV-1 typically establishes latency in the trigeminal ganglion, the nerve cluster behind the cheekbone that supplies sensation to the face. That is why HSV-1 outbreaks usually appear on or around the lips. HSV-2 typically settles into the sacral ganglia at the base of the spine, which is why HSV-2 outbreaks appear in the genital and anal area.

That residency preference is a tendency rather than a strict rule. If HSV-1 reaches the genital area through oral sex, it can establish itself in the sacral ganglia and cause genital herpes. The reverse happens too: HSV-2 transmitted to the mouth can cause oral lesions, though this is less common. Once the virus has chosen a residency site, future outbreaks emerge from that same site.

A few differences are clinically meaningful for someone trying to understand their own situation:

• Genital HSV-1 tends to recur far less often than genital HSV-2. The CDC STI Treatment Guidelines describe recurrences as much more frequent for HSV-2 than for HSV-1, particularly in the first few years after infection.
• HSV-2 sheds asymptomatically more often than HSV-1, so HSV-2-positive people can transmit the virus on more days when they have no visible symptoms.
• HSV-1 has been rising as a cause of first-episode genital herpes in younger adults, especially in higher-income countries where childhood oral HSV-1 infection is becoming less common.

HSV-1 vs HSV-2 at a glance

The table below summarizes how the two viruses compare on the points readers ask about most: where outbreaks appear, how each spreads, how common they are worldwide, and what each means in pregnancy. The global prevalence figures come from the World Health Organization.

Recognizing herpes symptoms

When symptoms do appear, the pattern is similar for both strains. The classic course of an outbreak runs through four phases:

1. Prodrome. Tingling, itching, or burning in the area where the outbreak will appear, usually 12 to 48 hours before any visible lesion.
2. Vesicle. Small fluid-filled blisters in clusters, typically 2 to 10 mm across.
3. Ulcer. Blisters break and form shallow open sores that can be painful.
4. Crust and heal. Sores crust over and heal. First outbreaks heal in 7 to 14 days; recurrences in 5 to 10 days.

First outbreaks are usually the most severe. They can include systemic symptoms: fever, body aches, swollen lymph nodes, headache, and general malaise. Many people describe the first episode as feeling like the flu with painful sores added on top. Recurrent outbreaks are typically milder, more localized, and shorter.

A large share of people infected with either HSV-1 or HSV-2 never have a recognized outbreak. The CDC's herpes information page notes that most people with genital herpes have no symptoms, or symptoms so mild they go unnoticed or are mistaken for a pimple or ingrown hair. Symptoms can also be confused with jock itch, a yeast infection, a urinary tract infection, or a hemorrhoid. That is one reason herpes is so widespread: most transmissions happen without anyone realizing they were infectious.

If your concern is specifically a sore around the mouth, the differential diagnosis includes canker sores (which sit inside the mouth on soft tissue, unlike cold sores, which sit on the lip border), angular cheilitis, impetigo, and contact dermatitis. A clinical exam during an active sore is the most reliable way to confirm a herpes lesion, and PCR swab testing of the sore at a clinic remains the laboratory gold standard.

How herpes spreads, and how it does not

Herpes spreads through direct contact with infected skin or mucous membranes. The specific routes:

• Skin-to-skin contact during a visible outbreak (highest transmission risk per contact event)
• Skin-to-skin contact during asymptomatic viral shedding (lower per-contact risk but high cumulative risk over time)
• Saliva contact for HSV-1: kissing, shared lip balm, shared utensils, shared cigarettes, shared mouthpieces
• Vaginal, anal, and oral sexual contact for HSV-2 (and for HSV-1 reaching the genitals)
• Mother to baby during vaginal birth, particularly if the mother has a primary infection during the third trimester

Things that do not transmit herpes, despite frequent worry:

• Toilet seats. The virus dies quickly on hard surfaces.
• Towels, clothing, or bedding after an outbreak has cleared.
• Casual social contact: handshakes, hugs, sharing a room.
• Pools, hot tubs, or saunas.
• Tears or sweat in normal amounts.

The most important nuance is asymptomatic shedding. People with HSV-1 or HSV-2 can release infectious virus from the skin or mucous membranes on days when they feel completely fine and look completely normal. Genital-shedding studies summarized in the CDC STI Treatment Guidelines show HSV-2-positive adults release virus on a meaningful share of asymptomatic days. Most new herpes transmissions happen during these symptom-free shedding periods, not during visible outbreaks. This is why public-health framing has shifted away from "avoid sex during outbreaks" toward continuous risk reduction through suppressive antivirals, condoms, and partner testing.

Recurrence and what triggers outbreaks

After the first infection, both viruses establish lifelong latency in nerve cells. They reactivate periodically, travel back down the nerve to the original site of infection, and cause an outbreak there. The triggers that prompt a reactivation are fairly consistent from person to person, and most people learn to recognize their own pattern over time.

Recurrence patterns differ by virus and by individual. Most people with genital HSV-2 have several outbreaks early on and gradually fewer over the years. The frequency of visible outbreaks tends to drop, and a meaningful minority stop having symptomatic recurrences entirely. The virus is still present and can still shed asymptomatically; it simply stops causing visible outbreaks.

Genital HSV-1 follows a similar but milder course: fewer early outbreaks and a faster decline in recurrence frequency. Oral HSV-1, the familiar cold sore, is highly variable. Some people get one or two cold sores a year, others get them monthly during stressful stretches, and some never have a recurrence after the initial childhood infection.

How herpes testing works

There are three main ways to diagnose herpes, and they answer different questions:

1. Visual examination during a visible outbreak. A clinician looks at the lesion and can often make a presumptive diagnosis from its appearance and your history. This identifies an outbreak but does not reliably distinguish HSV-1 from HSV-2.
2. PCR swab of an active lesion. A swab from the wet base of a fresh blister is sent to a laboratory for nucleic acid amplification testing. This is the most sensitive test during an outbreak and identifies the strain, but it only works while a sore is present, ideally before it crusts over.
3. Blood antibody testing (type-specific IgG). This looks for antibodies your immune system has made against HSV-1 or HSV-2 glycoprotein G, a protein on the surface of the virus. Antibodies typically take 6 to 12 weeks to develop, with a small share of people taking up to 16 weeks. Blood testing is the only way to learn your status when you have no lesion to swab.

Our at-home herpes kits are blood antibody tests that use a fingerstick sample on a lateral-flow strip, the same chemistry as a home pregnancy test. You clean a fingertip, prick it with the included lancet, place a drop of blood on the sample well of the cassette, add the buffer fluid, and wait about 15 minutes. Test and control lines develop in the result window, indicating HSV-1 antibodies, HSV-2 antibodies, both, or neither. These are lateral-flow immunoassays rather than laboratory NAAT or PCR tests; the technologies complement each other but are not interchangeable.

Two performance terms matter when you read the result. Sensitivity is the share of truly infected people the test correctly flags as positive; higher sensitivity means fewer false negatives. Specificity is the share of uninfected people correctly cleared as negative; higher specificity means fewer false positives. The CDC STI Treatment Guidelines describe sensitivity for HSV-2 type-specific IgG antibody tests in the 80% to 98% range. Specificity is more variable: it depends on the assay and on the magnitude of the positive signal, known as the index value. One widely used commercial assay, the HerpeSelect HSV-2 EIA, has an overall specificity of about 57 percent, dropping to roughly 40 percent for borderline-positive index values in the 1.1 to 2.9 range, per real-world data cited in the CDC STI Treatment Guidelines.

That variability is why the home cassette is a screening tool, and why the CDC recommends a confirmatory test, often the Western blot at a reference laboratory, before anyone acts on a positive screening result. The CDC also does not recommend routine HSV antibody screening for adults without symptoms. At low pretest probability, false positives can outnumber true positives, so the home antibody test is most informative after a known exposure, a partner's diagnosis, or unexplained recurrent genital symptoms, rather than as a general health check. A positive blood antibody test also reflects past exposure cumulatively: it cannot tell you when you were infected or which body region (oral, genital, or both) the infection lives in.

Which test fits your situation, and when to test

The most common cause of a misleading result is testing too soon. Your immune system needs time to build detectable IgG antibodies after a new infection, so a blood test taken inside the window can read negative even when a real infection is present. If you have a known or suspected exposure date, the practical rule is to wait at least 12 weeks before a home antibody test, and to repeat at 16 weeks if the first result is negative and you remain concerned.

A home antibody test is a good fit when:

• You had a known or suspected exposure 12 or more weeks ago and want your antibody status without a clinic visit.
• A current or recent partner has been diagnosed with HSV-1 or HSV-2 and you want to know whether you have also been exposed.
• You have unexplained recurrent genital symptoms and want a baseline antibody result before talking through further testing with a clinician.
• You are starting a new relationship and both partners want a baseline status check. You can reach our at-home herpes test for that purpose.

It is not the right tool when you currently have a fresh genital sore, blister, or ulcer. The right test then is a clinician-administered swab PCR of the lesion, which detects the virus directly and does not depend on antibody seroconversion. We do not sell swab-based herpes PCR tests, so for an active lesion a clinic visit is the better next step. The same applies if your suspected exposure was less than 12 weeks ago, or if you have no symptoms and no specific reason to test, where per CDC guidance routine antibody screening is not recommended.

Combined HSV-1 and HSV-2 Home Antibody Panel

Genital & Oral Herpes Rapid Self-Test Kit

$118.00

Fingerstick blood antibody test that screens for both HSV-1 and HSV-2 IgG antibodies on a single lateral-flow cassette. Best if you have not had a recognized outbreak and want to know your overall herpes status across both strains. Use 12 or more weeks after a suspected exposure for the most reliable result. A positive at-home screening result is best confirmed by a clinician's lab test before treatment decisions.

Test for HSV-1 and HSV-2

Reading your result without panic

The lateral-flow cassette will show a control line plus, depending on your antibody status, an HSV-1 line, an HSV-2 line, both, or neither. The control line confirms the test ran correctly. Without it, the result is invalid and you should repeat with a fresh cassette.

A negative result means no detectable IgG antibodies to the type tested. If at least 16 weeks have passed since your last possible exposure, this is generally informative. If less time has passed, plan a repeat test once you are past the window. A negative result does not tell you whether you may be exposed in the future or whether a different STI is present.

A positive result means IgG antibodies were detected, indicating past or current infection at some point. It does not tell you when the infection happened, whether the virus is currently active, or which body region (oral, genital, or both) the infection lives in. The next step is a confirmatory lab test through a clinician, particularly if you have no symptoms. Western blot at a reference lab remains the most specific confirmation method when a screening positive is questioned.

An invalid result (no control line, smudged window, or sample too small) means the test should be repeated. Common causes include not enough blood applied to the well, buffer skipped or measured incorrectly, or reading the cassette outside the timing window. Most kits ship with two cassettes for this reason.

Privacy, cost, and the practical side

The appeal of home herpes testing is straightforward: privacy, no clinic appointment, a fast result, and a lower out-of-pocket cost than an uninsured clinic visit, with no insurance claim or explanation-of-benefits that a policyholder might later see. A rapid lateral-flow blood antibody test returns a result in about 15 minutes. A mail-in lab kit, a different category we do not sell, typically takes 2 to 5 business days, and clinic-based serology usually takes several days through to about a week.

Cost varies by kit. Single-infection HSV-1 or HSV-2 tests are usually the lowest-cost option, a combined HSV-1 plus HSV-2 panel costs slightly more, and combination kits that bundle HSV with HIV, syphilis, and other blood-based infections offer the best per-test value if you want a wider screen. For screening after the window period, a correctly used rapid lateral-flow test is comparable in accuracy to lab serology, with the important caveat that a reactive result should be confirmed by a clinician.

One trade-off is worth naming: home testing skips the clinical conversation that usually accompanies a positive result. If your test is positive, a follow-up with a clinician matters for confirmation and for discussing treatment and partner notification. If a home result is reactive, booking a clinician appointment for confirmation is the practical next step before any treatment or disclosure decisions.

How to reduce herpes transmission risk

No behavior completely eliminates herpes transmission risk for someone who is sexually active with herpes-positive or untested partners. Several strategies meaningfully reduce it, and combining them works better than any single one:

• Daily suppressive antivirals for the herpes-positive partner. Per the CDC STI Treatment Guidelines, valacyclovir 500 mg once daily substantially reduces transmission to a susceptible partner in serodiscordant couples.
• Consistent condom use, which meaningfully reduces per-act HSV-2 transmission risk, with reduced effectiveness for areas a condom does not cover (the scrotum, the upper thighs, the perineum).
• Avoiding sex during outbreaks and prodromal symptoms, since per-act transmission risk is highest when lesions are visible or imminent.
• Disclosing status to partners so they can make informed decisions and consider antiviral suppression for themselves.
• Testing both partners before becoming sexually active, so each person knows their HSV status. This is most useful when starting a serious relationship.

Used together, suppressive antivirals plus condoms plus avoiding sex during outbreaks gives the strongest protection currently available short of abstaining, which is why clinicians often counsel stacking all three for serodiscordant couples planning long-term partnerships.

One related risk is worth naming: HSV-2 infection is associated with an increased risk of acquiring HIV through sexual exposure, per CDC and WHO surveillance. If you or a partner has HSV-2 and there is any concern about HIV exposure, add an HIV test to your plan rather than relying on the HSV result alone. For HSV-1 specifically, avoiding kissing during a visible cold sore prevents most transmission, and taking valacyclovir or acyclovir at the first prodromal tingle can shorten an outbreak by a day or two and reduce its peak severity.

HSV-2 Antibody Test for Genital Herpes Concerns

Genital Herpes-2 At-Home Rapid Self-Test Kit

$59.00

Fingerstick blood antibody test specific for HSV-2, the strain most often responsible for genital herpes. Useful 12 or more weeks after a suspected genital exposure or a partner's HSV-2 diagnosis. Private, at home, results in roughly 15 minutes. Confirm any positive result with a clinician-ordered lab test.

Test for HSV-2

Living with herpes and what comes after a positive

Herpes is not a serious medical condition for most adults. Outbreaks are uncomfortable, and stigma is real and outsized relative to the physical impact. For most healthy adults the day-to-day reality is mild: occasional outbreaks, manageable with antivirals if needed, and no effect on lifespan or fertility.

Antivirals do not cure HSV. Oral acyclovir, valacyclovir, and famciclovir suppress replication, shorten outbreaks, reduce recurrence frequency, and lower transmission risk to partners, but the virus stays in nerve tissue for life. Per the CDC STI Treatment Guidelines, valacyclovir 500 mg taken daily is the standard suppressive regimen, while episodic therapy taken at the first sign of an outbreak is an alternative when recurrences are infrequent.

Some situations need extra attention:

• Pregnancy. A new HSV infection during the third trimester is the highest-risk scenario for neonatal herpes, which is rare but serious. Discuss your status with your obstetric provider; many recommend suppressive therapy from week 36 onward in HSV-2-positive pregnancies, and a cesarean delivery if active lesions are present at the time of labor.
• Compromised immune systems. People with HIV, organ transplants, or active chemotherapy can have more severe and more frequent outbreaks, and long-term antiviral suppression is often used.
• First-time outbreaks can be severe enough to warrant a clinic visit for prescription antivirals; over-the-counter creams are not enough for a primary infection.

If a home antibody test comes back positive, the right follow-up is a clinician visit to confirm with a lab test, to discuss whether suppressive or episodic therapy fits your pattern, and to walk through partner notification. The NHS genital herpes guidance offers a similar treatment framework, and patient-facing summaries such as MedlinePlus can help, particularly for HSV-2 where stigma has historically been heavier.

Type-specific serologic tests can be useful for partners of persons who have genital herpes. Screening for HSV-1 or HSV-2 infection in the general population is not indicated.

Common myths worth correcting

Stigma drives a lot of misinformation about herpes, and a few beliefs come up again and again. One of the most stubborn is that only "certain types of people" get herpes. That is false. NHANES 2015 to 2016 surveillance data published by the National Center for Health Statistics found roughly 47.8 percent of US adults aged 14 to 49 carry HSV-1 and 11.9 percent carry HSV-2. Globally the WHO estimates HSV-1 prevalence at about 64 percent of people under age 50. It is among the most common viral infections in the world and does not track to any one demographic. The misconceptions below come up almost as often.

Your next step

What to do now depends on whether you have symptoms and how long it has been since a possible exposure. Use the quick guide below to find the right starting point, then confirm anything that needs confirming with a clinician.

1. World Health Organization. Herpes simplex virus fact sheet, including global prevalence estimates for HSV-1 (about 3.8 billion people under 50) and HSV-2 (about 520 million aged 15 to 49) and the clinical course of infection.
2. US Centers for Disease Control and Prevention. Herpes information page covering symptoms, transmission, testing, and treatment, source for the statement that most people with genital herpes have no symptoms or symptoms so mild they go unnoticed.
3. US Centers for Disease Control and Prevention. STI Treatment Guidelines, Genital Herpes. Window-period guidance, the 80% to 98% sensitivity range, the HerpeSelect HSV-2 EIA overall specificity (about 57 percent) and lower specificity at low-positive index values (about 40 percent at index 1.1 to 2.9), the recommendation against routine asymptomatic screening, Western blot confirmation guidance, the recurrence-frequency comparison, and the valacyclovir 500 mg suppressive regimen that reduces transmission in serodiscordant couples.
4. National Center for Health Statistics. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14 to 49: United States, 2015 to 2016. NCHS Data Brief No. 304. Source for the 47.8 percent HSV-1 and 11.9 percent HSV-2 US seroprevalence figures.
5. NHS. Genital herpes overview, symptoms, and treatment guidance for the UK general public.
6. MedlinePlus, US National Library of Medicine. Genital herpes patient information page, a plain-language summary of clinical features, testing, and treatment.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.